Percent decreases in Fc-LDL-C and increases in HDL-C with anacetrapib were similar ( magnitude of difference generally < 1/5 of the overall treatment effect ) across subgroups by age , gender , diabetes status , lipid-modifying regimen , and baseline Fc-LDL-C , HDL-C , or TG .